Alector (ALEC)
NASDAQ:ALEC
Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$2.57
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.57
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$1.09 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)552.70K
Market Cap
$245.37M
Enterprise Value$196.29M
Total Cash (Recent Filing)$206.51M
Total Debt (Recent Filing)$34.55M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Jul 30, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding111,025,185
10 Day Avg. Volume702,603
30 Day Avg. Volume552,702
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue10.66
Enterprise Value/Gross Profit12.02
Enterprise Value/Ebitda-1.57
Forecast
1Y Price Target
$3.63Price Target Upside41.05% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$6.98M
Bulls Say, Bears Say
Bulls Say
Differentiated Antibody MechanismThe lead anti‑amyloid antibody retaining full effector function supports more efficient plaque clearance and differentiates the program from competitors on potential efficacy grounds.
Funding For Clinical AdvancementSecured funding to advance two platform‑derived assets into clinical testing supports progression of the pipeline toward tangible clinical readouts.
Platform Pivot And StrategyA shift to a proprietary blood‑brain‑barrier platform and concentration on an anti‑amyloid antibody plus a tau siRNA program may concentrate value and clarify the development strategy.
Bears Say
Analyst Caution And Limited CatalystsAnalyst recommendations remain cautious because the pipeline offers limited catalysts for valuation re‑rating, which may restrict upside absent clear clinical validation.
Binary Risk From Interim Futility ReadoutAn interim futility analysis in the Phase 2 Alzheimer's study represents a binary clinical readout that could drive significant stock volatility if results are unfavorable.
Recent Late‑stage Trial FailureDiscontinuation of a late‑stage therapy following trial failure undermines confidence in the near‑term pipeline and raises questions about program reliability.
Alector News
ALEC FAQ
What was Alector’s price range in the past 12 months?
Alector lowest stock price was $1.09 and its highest was $3.40 in the past 12 months.
What is Alector’s market cap?
Alector’s market cap is $245.37M.
When is Alector’s upcoming earnings report date?
Alector’s upcoming earnings report date is Jul 30, 2026 which is in 61 days.
How were Alector’s earnings last quarter?
Alector released its earnings results on May 07, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.078.
Is Alector overvalued?
According to Wall Street analysts Alector’s price is currently Undervalued.
Does Alector pay dividends?
Alector does not currently pay dividends.
What is Alector’s EPS estimate?
Alector’s EPS estimate is -0.22.
How many shares outstanding does Alector have?
Alector has 111,025,185 shares outstanding.
What happened to Alector’s price movement after its last earnings report?
Alector reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -13.934%.
Which hedge fund is a major shareholder of Alector?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.63 (41.05% Upside)
$3.63 (41.05% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 94.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.40%
12-Months-Change
Fundamentals
Return on Equity
-295.17%
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Alector
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$3.63
▲(41.05% Upside)
Technical Analysis
Ownership Overview
7.47% Insiders
11.53% Mutual Funds
38.59% Other Institutional Investors
33.42% Public Companies and
Individual Investors